Missing out on effective care in idiopathic pulmonary fibrosis: Racial inequality in access to anti-fibrotic therapy

被引：0
|
作者：
Pascoe, Amy [1 ]
Smallwood, Natasha [1 ,2 ]
机构：
[1] Monash Univ, Cent Clin Sch, Resp Res, Alfred, Vic, Australia
[2] Alfred Hosp, Dept Resp & Sleep Med, Prahran, Vic, Australia
来源：
RESPIROLOGY | 2023年 / 28卷 / 11期
关键词：
antifibrotic agents; health disparities; health inequities; idiopathic pulmonary fibrosis; interstitial lung disease; mortality; social determinants of health; DISPARITIES; COPD;
D O I：
10.1111/resp.14594
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
See related article
引用
收藏
页码：978 / 979
页数：2
相关论文
共 35 条
  • [21] Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis
    Zhao, Joy
    Fares, Joseph
    George, Gautam
    Maheu, Arlene
    Loizidis, Giorgos
    Roman, Jesse
    Kramer, Daniel
    Li, Michael
    Summer, Ross
    RESPIROLOGY, 2023, 28 (11) : 1036 - 1042
  • [22] Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats
    Amirkhosravi, Arian
    Goki, Maryamossadat Mirtajaddini
    Heidari, Mahmoud Reza
    Karami-Mohajeri, Somayyeh
    Iranpour, Maryam
    Torshabi, Maryam
    Mehrabani, Mitra
    Mandegary, Ali
    Mehrabani, Mehrnaz
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [23] The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis
    Liang, Chunlian
    Li, Xiuli
    Zhang, Lin
    Cui, Dajiang
    Quan, Xiaojuan
    Yang, Weilin
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2015, 99 (02) : 279 - 285
  • [24] What proportion of patients with Idiopathic Pulmonary Fibrosis fall outside UK prescribing criteria for anti-fibrotic treatment? A UK specialist centre review
    Brereton, Christopher J.
    Pontoppidan, Katarina
    Wallis, Tim
    Richeldi, Luca
    Jones, Mark G.
    Fletcher, Sophie V.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [25] SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis
    Tzouvelekis, Argyris
    Yu, Guoying
    Herazo-Maya, Jose
    Woolard, Tony
    Zhang, Yi
    Lee, Hojin
    Lee, Patty
    Herzog, Erica
    Bennett, Anton
    Kaminski, Naftali
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [26] Macrophage-based delivery of anti-fibrotic proteins alleviates bleomycin-induced pulmonary fibrosis in mice
    Liu, Huiying
    Yang, Cuiping
    Gao, Yun
    Zhang, Xueli
    Wang, Min
    Yu, Xinting
    Wang, Weidong
    Xie, Lixin
    Tang, Ping
    Yin, Xiushan
    Bai, Changqing
    Zhang, Luo
    BIOENGINEERING & TRANSLATIONAL MEDICINE, 2023, 8 (05)
  • [27] Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model
    Li, Xiaohe
    Lv, Ziwei
    Huang, Kai
    Gan, Wenhua
    Gao, Shaoyan
    Yang, Bo
    Helian, Kaiyue
    Zhou, Honggang
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [28] Anti-acid therapy in Idiopathic Pulmonary Fibrosis: to treat or not to treat?
    Kolilekas, Likurgos
    Manali, Effrosyni D.
    Papiris, Spyros A.
    Bouros, Demosthenes
    PNEUMON, 2016, 29 (03) : 196 - 199
  • [29] Effects of Cheonwangbosim-dan in a Mouse Model of Chronic Obstructive Pulmonary Disease: Anti-Inflammatory and Anti-Fibrotic Therapy
    Kang, Jee Hyun
    Jung, Eunhye
    Hong, Eun-Ju
    Baek, Eun Bok
    Lee, Mee-Young
    Kwun, Hyo-Jung
    APPLIED SCIENCES-BASEL, 2023, 13 (03):
  • [30] Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
    Yang, Mei
    Dong, Jiajia
    An, Jing
    Liu, Lin
    Chen, Lei
    JOURNAL OF THORACIC DISEASE, 2021, 13 (10) : 5776 - +
1234